PT  - JOURNAL ARTICLE
AU  - TOSHIO INUI
AU  - KAORI MAKITA
AU  - HIRONA MIURA
AU  - AKIKO MATSUDA
AU  - DAISUKE KUCHIIKE
AU  - KENTARO KUBO
AU  - MARTIN METTE
AU  - YOSHIHIRO UTO
AU  - TAKAHITO NISHIKATA
AU  - HITOSHI HORI
AU  - NORIHIRO SAKAMOTO
TI  - Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy
DP  - 2014 Aug 01
TA  - Anticancer Research
PG  - 4589--4593
VI  - 34
IP  - 8
4099  - http://ar.iiarjournals.org/content/34/8/4589.short
4100  - http://ar.iiarjournals.org/content/34/8/4589.full
SO  - Anticancer Res2014 Aug 01; 34
AB  - Background: Gc protein-derived macrophage-activating factor (GcMAF) occurs naturally in the human body. It has various functions, such as macrophage activation and antitumor activities. Recently, immunotherapy has become an attractive new strategy in the treatment of cancer. GcMAF-based immunotherapy can be combined with many other therapies. Sonodynamic therapy (SDT) using low-intensity ultrasound is a novel therapeutic modality. Ultrasound has been demonstrated to activate a number of sonosensitive agents allowing for the possibility of non-invasive targeted treatment for both superficial and deep-seated tumors. The current case study demonstrates that GcMAF and SDT can be used in combination with conventional therapies in patients with metastatic cancer, especially where treatment options are limited due to factors such as toxicity. This case study also suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SDT, to be used in combination with GcMAF immunotherapy as a systemic treatment.